Efficacy and safety of Shenqi Fuzheng Injection combined with transcatheter arterial chemoembolization for primary liver cancer：a Meta analysis
YANG Wanting HOU Encun
The Second Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530011, China
Abstract：Objective To systematically evaluate the efficacy and safety of Shenqi Fuzheng Injection combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods The method of systematic review from the Cochrane library was adopted and clinical controlled trials were retrieved by computer in the Cochrane library, Medline, Embase, PubMed, Wanfang database, Chinese science and technology journal full-text database retrieval (CNKI), China journal full-text database (VIP), etc. "Shenqi Fuzheng Injection", "liver cancer" and "intervention" were used as the keywords to find clinical randomized controlled trials of Shenqi Fuzheng Injection combined with TACE in the treatment of primary liver cancer which were open published from the establishment of database to December 2016. The inclusion and exclusion criteria were used to select the literature by two researchers, the full texts were sought, through quality assessment of literatures and data extraction, finally, the literatures were analyzed statistically by Review Manger 5.2 software eventually. Results There were 7 RCT studies and a total of 466 patients were included. Meta-analysis results showed that compared with single TACE in the treatment of primary hepatocellular carcinoma, the efficiency (RR = 1.45, 95%CI: 1.01-2.07, P = 0.04), the quality of life (RR = 2.29, 95%CI: 1.65-3.17, P ＜ 0.01), CD4+/CD8+ (MD = 0.28, 95%CI: 0.09-0.47, P = 0.003) of Shenqi Fuzheng Injection combined with TACE in the treatment of primary hepatocellular carcinoma were significantly improved, the decrease of white blood cells (RR = 0.68, 95%CI: 0.56-0.83, P = 0.0001) and the occurrence rate of gastrointestinal tract reaction (RR = 0.69, 95%CI: 0.51-0.95, P = 0.02) of which were also lower than TACE. Conclusion Shenqi Fuzheng Injection can improve the efficacy and safety of TACE in the treatment of primary liver cancer.
2017, Vol. 14 
京公网安备 11010502046598号